Vaxcyte completes enrollment in OPUS-1 and OPUS-2 Phase 3 trials of VAX-31 in about 5,300 adults

Reuters

Mar 23

Vaxcyte completes enrollment in OPUS-1 and OPUS-2 Phase 3 trials of VAX-31 in about 5,300 adults

Vaxcyte reported that enrollment is complete in the OPUS-1 Phase 3 trial of VAX-31 with about 4,000 participants and the OPUS-2 Phase 3 trial with about 1,300 participants.
OPUS-1 is a randomized, double-blind, active-controlled noninferiority study comparing VAX-31 with Capvaxive (PCV21) and Prevnar 20 (PCV20) in pneumococcal-naïve adults ages 50 and older, with a separate cohort ages 18–49.
Participants ages 50 and older were randomized 1:1:1 to VAX-31, PCV21, or PCV20, while adults ages 18–49 were randomized 3:1 to VAX-31 or PCV20.
Topline safety, tolerability, and immunogenicity results from OPUS-1 are expected in the fourth quarter of 2026.
OPUS-2 is evaluating concomitant administration of VAX-31 with a seasonal influenza vaccine, with results expected in the first half of 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vaxcyte Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603230830PRIMZONEFULLFEED9676418) on March 23, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2621970553"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2621970553\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2621970553?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-23 20:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2621970553","market":"us","top_or_hot":-1,"title":"Vaxcyte completes enrollment in OPUS-1 and OPUS-2 Phase 3 trials of VAX-31 in about 5,300 adults","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Vaxcyte completes enrollment in OPUS-1 and OPUS-2 Phase 3 trials of VAX-31 in about 5,300 adults\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Vaxcyte reported that enrollment is complete in the OPUS-1 Phase 3 trial of VAX-31 with about 4,000 participants and the OPUS-2 Phase 3 trial with about 1,300 participants.\n        </li>\n<li>\n          OPUS-1 is a randomized, double-blind, active-controlled noninferiority study comparing VAX-31 with Capvaxive (PCV21) and Prevnar 20 (PCV20) in pneumococcal-naïve adults ages 50 and older, with a separate cohort ages 18–49.\n        </li>\n<li>\n          Participants ages 50 and older were randomized 1:1:1 to VAX-31, PCV21, or PCV20, while adults ages 18–49 were randomized 3:1 to VAX-31 or PCV20.\n        </li>\n<li>\n          Topline safety, tolerability, and immunogenicity results from OPUS-1 are expected in the fourth quarter of 2026.\n        </li>\n<li>\n          OPUS-2 is evaluating concomitant administration of VAX-31 with a seasonal influenza vaccine, with results expected in the first half of 2027.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vaxcyte Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603230830PRIMZONEFULLFEED9676418) on March 23, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaxcyte completes enrollment in OPUS-1 and OPUS-2 Phase 3 trials of VAX-31 in about 5,300 adults</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaxcyte completes enrollment in OPUS-1 and OPUS-2 Phase 3 trials of VAX-31 in about 5,300 adults\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-23 20:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Vaxcyte completes enrollment in OPUS-1 and OPUS-2 Phase 3 trials of VAX-31 in about 5,300 adults\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Vaxcyte reported that enrollment is complete in the OPUS-1 Phase 3 trial of VAX-31 with about 4,000 participants and the OPUS-2 Phase 3 trial with about 1,300 participants.\n        </li>\n<li>\n          OPUS-1 is a randomized, double-blind, active-controlled noninferiority study comparing VAX-31 with Capvaxive (PCV21) and Prevnar 20 (PCV20) in pneumococcal-naïve adults ages 50 and older, with a separate cohort ages 18–49.\n        </li>\n<li>\n          Participants ages 50 and older were randomized 1:1:1 to VAX-31, PCV21, or PCV20, while adults ages 18–49 were randomized 3:1 to VAX-31 or PCV20.\n        </li>\n<li>\n          Topline safety, tolerability, and immunogenicity results from OPUS-1 are expected in the fourth quarter of 2026.\n        </li>\n<li>\n          OPUS-2 is evaluating concomitant administration of VAX-31 with a seasonal influenza vaccine, with results expected in the first half of 2027.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vaxcyte Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603230830PRIMZONEFULLFEED9676418) on March 23, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B3QW5Z07.USD","symbol_name":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nNDL2YY9Xl:1","article_id":"2621970553","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2621970553","pubTimestamp":1774269076,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Vaxcyte reported that enrollment is complete in the OPUS-1 Phase 3 trial of VAX-31 with about 4,000 participants and the OPUS-2 Phase 3 trial with about 1,300 participants.OPUS-1 is a randomized, double-blind, active-controlled noninferiority study comparing VAX-31 with Capvaxive  and Prevnar 20  in pneumococcal-nave adults ages 50 and older, with a separate cohort ages 18–49.Participants ages 50 and older were randomized 1:1:1 to VAX-31, PCV21, or PCV20, while adults ages 18–49 were randomized 3:1 to VAX-31 or PCV20.Topline safety, tolerability, and immunogenicity results from OPUS-1 are expected in the fourth quarter of 2026.OPUS-2 is evaluating concomitant administration of VAX-31 with a seasonal influenza vaccine, with results expected in the first half of 2027.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","PCVX":"Vaxcyte, Inc.","IE0009354923.USD":"JANUS HENDERSON US VENTURE \"A2\" (USD) ACC","LU0053671581.USD":"摩根大通美国小盘成长股 A(dist)","BK4588":"碎股","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","BK4139":"生物科技","BK4585":"ETF&股票定投概念","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","BK4112":"金融交易所和数据","NDAQ":"纳斯达克OMX交易所","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","IE00BN0W2W23.USD":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (USD) ACC","IE00BN0W2V16.EUR":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (EUR) ACC","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","IE00BN0W2T93.GBP":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (GBP) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD"},"translate_title":"Vaxcyte在约5,300名成人中完成了VAX-31的OPUS-1和OPUS-2 3期试验的入组","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"PCVX":0.9},"content_text":"Vaxcyte completes enrollment in OPUS-1 and OPUS-2 Phase 3 trials of VAX-31 in about 5,300 adults\n    \n\n\n          Vaxcyte reported that enrollment is complete in the OPUS-1 Phase 3 trial of VAX-31 with about 4,000 participants and the OPUS-2 Phase 3 trial with about 1,300 participants.\n        \n\n          OPUS-1 is a randomized, double-blind, active-controlled noninferiority study comparing VAX-31 with Capvaxive (PCV21) and Prevnar 20 (PCV20) in pneumococcal-naïve adults ages 50 and older, with a separate cohort ages 18–49.\n        \n\n          Participants ages 50 and older were randomized 1:1:1 to VAX-31, PCV21, or PCV20, while adults ages 18–49 were randomized 3:1 to VAX-31 or PCV20.\n        \n\n          Topline safety, tolerability, and immunogenicity results from OPUS-1 are expected in the fourth quarter of 2026.\n        \n\n          OPUS-2 is evaluating concomitant administration of VAX-31 with a seasonal influenza vaccine, with results expected in the first half of 2027.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vaxcyte Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603230830PRIMZONEFULLFEED9676418) on March 23, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}